Explore the Agenda
7:30 am Check-In & Morning Coffee
8:20 am Chair’s Opening Remarks
Navigating the Evolving TPD Landscape to Understand Future Directions & Drive the Next-Generation of Proximity Therapeutics
8:30 am Panel Discussion: The TPD Investment Landscape: Lessons from Deals in 2025 & Expectations for 2026
9:15 am Discovery of a VHL-Based Molecular Glue Degrader Targeting GEMIN3 Using Picowell RNA-Sequencing
9:45 am Illuminating New Insights in Targeted Protein Degradation Kinetics, Mechanisms, & Selectivity
10:15 am Expanding Targeted Glue Applications by Recruiting Novel E3 Ligases Across Diverse Targets
10:45 am Morning Break & Networking
Track A: Discovery
Utilizing Novel Discovery Platforms to Find Potent & Selective Molecular Glues to Progress Cures Against Autoimmune & Cancer Indication
11:30 am Orally Bioavailable NRF2 Molecular Glue Degrader Effective in KEAP1-Mutant Cancer
Chief Executive Officer, Arpeggio Bio
- Novel HTS Transcriptomics screen identifies initial NRF2 hit
- Hit and Analog induces an interaction between NRF2 and BTrCP
- Optimized analogs lead to significant in vivo activity in multiple lung cancer models with very favorable drug-like and safety profiles
12:00 pm Targeting Mutant KRAS Oncoproteins with Molecular Glues: A TUBE-Based Screen Identifies a Novel Degradation Pathway
Vice President, Research and Development, Lifesensors
- Tandem Ubiquitin Binding Entity (TUBE) platform to discover novel molecular glues targeting mutant KRAS
- KRAS Mol Glue, coopting a novel E3 ligase to ubiquitinate and degrade mutant KRAS
- Pan KRAS degrader downregulates MAPK signaling
- Chain selective poly-ubiquitin TUBEs, K48 or K63, elucidate MOA of the compounds
Track B: Pre-Clinical Development
Track C: Translational & Clinical Development
12:30 pm Lunch Break & Networking
Track A: Discovery
Designing Innovative Activating Molecular Glues Through Structure-Guided Design & AI/ML to Unlock New Therapeutic Opportunities
1:30 pm Structure-Based Development of Non-Degrader Molecular Glues to Selectively Stabilize a Tumor Suppressor Phosphatase Complex
Head of Structural Biology (Rappta Therapeutics); Professor (Case Western Reserve University), Rappta Therapeutics
- A tool compound (DT-061) selectively stabilizes B56α-containing PP2A heterotrimers, enhancing their pro-apoptotic functions and driving dephosphorylation of its oncogenic substrate, c-Myc
- Cryo-EM structure of DT-061 bound to its binding pocket identifies a trimeric interface of PP2A subunits, defining the molecular basis for its selective stabilization and therapeutic potential
- Structure-based drug design was used to develop new chemical compounds that also behave like molecular glues, but with improved pharmacokinetic properties
2:00 pm Panel Discussion: Cracking the Code: Understanding & Measuring Cooperativity in Induced Proximity Modalities
Vice President & Head of Chemistry, Rapafusyn Pharmaceuticals
Director - Biophysics, High Throughput Screening & Oncology, Pfizer
Exe, Revolution Medicines
2:30 pm Building A Computational Design Platform For Any Molecular Glue
Chief Executive Officer, Ternary Therapeutics
- Discussing the requirements of a successful molecular glue design platform
- Blending the speed and scalability of Machine Learning with the accuracy of Physics-Based Methods for optimal protein-protein matching and ternary complex structure prediction
- Computational design and experimental validation of optimised molecular glue degraders and activators
Track B: Pre-Clinical Development
Track C: Translational & Clinical Development
3:00 pm Afternoon Break & Networking
3:30 pm Harnessing Degradation to Achieve Selectivity & First-in-Class Targeting of Challenging Chromatin Regulatory Proteins
Securing the Future of Induced Proximity with Pioneering Academic Breakthroughs & Emerging Biotech Pioneers Ready to Take 2026 by Storm
4:00 pm Degrader Antibody Conjugates (DACs): Targeted Protein Degraders (TPD) as Next-Generation Antibody Drug Conjugate (ADC) Payloads
- By combining the ability of a TPD to selectively remove a protein of interest with the cell specificity of antibodies, DACs have the potential for greater efficacy and broader therapeutic application than traditional cytotoxic ADC payloads
- Improved safety can be achieved through the layers of specificity provided by degrader selectivity, ligase expression, and antibody targeting
- DACs are more than the sum of their parts and are best optimized combinatorially
- Antibody delivery can expand the applicability of novel ligase ligands in TPD beyond those commonly used for oral small molecules